-+ 0.00%
-+ 0.00%
-+ 0.00%

HCW BIOLOGICS REACHES MILESTONES FOR ITS PROPRIETARY TETRAVALENT SECOND-GENERATION T-CELL ENGAGER PROGRAM ON TRACK TO INITIATE CLINICAL TRIALS IN FIRST HALF 2027

Reuters·07/23/2026 12:00:02

Please log in to view news